Prezista (darunavir) / J&J 
Welcome,         Profile    Billing    Logout  
 32 Diseases   11 Trials   11 Trials   1696 News 


«12...4567891011121314...2021»
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] IN VITRO MODEL TO ASSESS ANTIRETROVIRAL THERAPY ON ADIPOCYTE BIOLOGY () -  Mar 18, 2021 - Abstract #CROI2021CROI_724;    
    The observed decrease in leptin, a major satiety hormone, in the STAY group may help explain the increased weight gain observed in individuals taking InSTIs. This model can help define mechanisms by which ART causes adverse metabolic effects and used in pre-clinical applications to test potential, unintended adipocyte-specific effects of future ART.
  • ||||||||||  [VIRTUAL] EFFECTIVENESS OF RECOMMENDED 3-DRUG REGIMENS FOR TREATING ADVANCED HIV INFECTION () -  Mar 18, 2021 - Abstract #CROI2021CROI_615;    
    The effectiveness of one of the newest 3-drug regimen (3DR), bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF), was therefore compared to other 3DRs that included boosted darunavir (bDRV), dolutegravir (DTG) or elvitegravir/cobicistat (EVG/c) among ART-naïve PLWH with CD4 count <200 cells/μL. Among PLWH with advanced HIV infection initiating ART, those on B/F/TAF appeared less likely to discontinue their regimen compared to other 3DRs (unadjusted) and were numerically more likely to achieve virologic suppression compared to bDRV but did not differ from those on DTG or EVG/cbased 3DR (adjusted).
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] IMPACT OF ANTIRETROVIRAL REGIMENS ON MORTALITY IN PATIENTS WITH ADVANCED HIV DISEASE () -  Mar 18, 2021 - Abstract #CROI2021CROI_614;    
    The most frequently third-drug was darunavir (73%), efavirenz (70.9%) and dolutegravir (47%), respectively. In this large real-life cohort study, a lower mortality and a less rate of discontinuation in patients treated with InSTIs regimens were observed among naive patients with advance HIV disease.
  • ||||||||||  lenacapavir (GS CA2) / Gilead
    [VIRTUAL] ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR () -  Mar 18, 2021 - Abstract #CROI2021CROI_338;    
    In addition, mutants with resistance to LEN were found not cross-resistant to PIs, and LEN susceptibility was similar across isolates with diverse subtypes. These data emphasize the beneficial profile of LEN as a potential treatment option for people living with HIV.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: 48 WKS PRIMARY OUTCOME () -  Mar 18, 2021 - Abstract #CROI2021CROI_216;    
    This finding is important for patients switching from NNRTI to dolutegravir with NRTIs after known treatment failure; and for programmes switching stable patients systematically from NNRTI to dolutegravir-based regimens without VL and resistance testing. Tenofovir can be maintained in second-line therapy without switching to zidovudine, with advantages for patients and Programmes.
  • ||||||||||  lenacapavir (GS CA2) / Gilead
    [VIRTUAL] CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS () -  Mar 18, 2021 - Abstract #CROI2021CROI_211;    
    The magnitude of inhibition via COBI, DRV/COBI, and VORI is not considered to be clinically relevant, supporting coadministration of LEN with potent inhibitors of CYP3A and P-gp without dose modification. However, potent inducers of CYP/P-gp/UGT, such as RIF, should be avoided.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Journal:  A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient. (Pubmed Central) -  Mar 5, 2021   
    A 58-year-old 2 years post-kidney transplant recipient, with maintenance immunosuppression of tacrolimus, mycophenolate mofetil (MMF), and prednisolone, presented with acute diarrhea which followed by fever on day 12...Darunavir together with ritonavir, hydroxychloroquine, azithromycin, and favipiravir was initiated on the first day of admission at primary hospital...Symptoms of pneumonia were improved which no oxygen treatment required from day 10 of hospitalization. Drug interaction between tacrolimus and anti-viral treatment lead to severely high level of tacrolimus which caused reversible acute kidney injury (AKI) after supportive treatment.
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study. (Pubmed Central) -  Feb 23, 2021   
    To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH ≥55 years. DDI magnitudes were comparable to those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar.
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD)
    Retrospective data, Review, Journal:  Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis. (Pubmed Central) -  Feb 20, 2021   
    Moreover, the pairwise (direct only) comparisons did not show a significant difference between doravirine (all doses) and other treatment groups. Doravirine could be counted as an efficacious, safe, and well-tolerated treatment option that is preferable to other regimens for the initial therapy of individuals with HIV-1 infection.
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Darunavir: A comprehensive profile. (Pubmed Central) -  Feb 20, 2021   
    This article discusses, by a critical extensive review of the literature, the description of darunavir in terms of its names, formulae, elemental composition, appearance, and use in the treatment of HIV-infected patients. The article also discusses the methods for preparation of darunavir, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information.
  • ||||||||||  Prezista (darunavir) / J&J
    Clinical, Journal:  Synthesis of 3,3'-methylenebis(4-hydroxyquinolin-2(1H)-ones) of prospective anti-COVID-19 drugs. (Pubmed Central) -  Feb 18, 2021   
    X-ray structure analysis proved the anti-form of the obtained compounds, which were stabilized by the formation hydrogen bond. Molecular docking calculations showed that most of the synthesized compounds possessed good binding affinity to the SARS-CoV-2 main protease (M) in comparable to Darunavir.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Journal:  Identification of potential antivirals against SARS-CoV-2 using virtual screening method. (Pubmed Central) -  Feb 18, 2021   
    Furthermore, some approved structural analogues, such as Telbivudine, Tenofovir, Amprenavir, Fosamprenavir, etc., were predicted as similar drugs which may also be used for treating viral infections. We highly recommend these drug candidates as potential fighters against the deadly SARS-CoV-2 virus, and suggest in vivo trials for experimental validation of our findings.
  • ||||||||||  Review, Journal:  Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. (Pubmed Central) -  Feb 13, 2021   
    These drugs have been approved for a different indication and belong to a diverse category such as anti-malarial/anti-parasitic, anti-retroviral/anti-viral, anti-cancer, or against rheumatoid arthritis. Although, the vaccine would be an ideal option for providing active immunity against the SARS-CoV-2, but considering the current situation, drug repurposing and convalescent plasma therapy and repurposed drugs are the most viable option against SARS-CoV-2.
  • ||||||||||  ritonavir / Generic mfg.
    Journal:  Biochemical Characterization, Specificity and Inhibition Studies of HTLV-1, HTLV-2, and HTLV-3 Proteases. (Pubmed Central) -  Feb 11, 2021   
    We investigated the effects of different HIV-1 PR inhibitors (atazanavir, darunavir, DMP-323, indinavir, ritonavir, and saquinavir) on enzyme activities, and inhibitory potentials of IB-268 and IB-269 inhibitors that were previously designed against HTLV-1 PR. Comparative biochemical analysis of HTLV-1, -2, and -3 PRs may help understand the characteristic similarities and differences between these enzymes in order to estimate the potential of the appearance of drug-resistance against specific HTLV-1 PR inhibitors.
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Development of darunavir proliposome powder for oral delivery by using box-bhenken design. (Pubmed Central) -  Feb 5, 2021   
    The results showed that pro-liposome powder containing Darunavir can efficiently deliver in to the blood stream. This drug delivery system has been designed as a novel platform for potential oral delivery of drugs having poor water solubility and high first-pass metabolism.
  • ||||||||||  Prezista (darunavir) / J&J
    Clinical, Observational data, Journal:  Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection. (Pubmed Central) -  Feb 3, 2021   
    This drug delivery system has been designed as a novel platform for potential oral delivery of drugs having poor water solubility and high first-pass metabolism. Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.
  • ||||||||||  ritonavir / Generic mfg.
    [VIRTUAL] Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency Due to an Interaction Between Fluticasone and Ritonavir. (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_744;    
    A treatment with fluticasone 1 inh / 24h, salbutamol on demand, darunavir 800 mg / day and ritonavir 100 mg / day.He had known lipodystrophy since 2001 and the abdominal perimeter was controlled, showing an increase in it...It was restarted, antibiotic treatment was prescribed, and she was discharged home with a new regimen of antiretrovirals (raltegravir, tenofovir, and abacavir)...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  Prezista (darunavir) / J&J, Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
    Journal:  Weight gain in people living with HIV switched to dual therapy: changes in body fat mass. (Pubmed Central) -  Jan 26, 2021   
    Despite lower weight gain (0.70 kg, IQR -0.8 to 4.0, P = 0.28), fat mass increase was similar in the darunavir/lamivudine group. Baseline fat mass and CD4 counts were the only factors explaining fat mass gain.
  • ||||||||||  Trial completion date, Trial termination:  RESIST-2: 2nd-line ART for HIV-2 Infection (clinicaltrials.gov) -  Jan 25, 2021   
    P=N/A,  N=152, Terminated, 
    Our results could contribute to the development of potentials drugs inhibiting SARS-CoV-2. Trial completion date: Jul 2022 --> May 2020 | Active, not recruiting --> Terminated; COVID-19 and Funding
  • ||||||||||  ritonavir / Generic mfg.
    Review, Journal:  Review of pharmacologic and immunologic agents in the management of COVID-19. (Pubmed Central) -  Jan 20, 2021   
    This review provides an appraisal of the current evidence for rational use of frontline therapeutics in the management of COVID-19. It also includes updates regarding COVID-19 immunotherapy and vaccine development.
  • ||||||||||  grazoprevir (MK-5172) / Merck (MSD), Sunvepra (asunaprevir) / BMS
    Review, Journal:  Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. (Pubmed Central) -  Jan 13, 2021   
    For the majority of these drugs, direct clinical evidence on their efficacy for the treatment of COVID-19 is lacking. Future clinical studies examining these drugs might come to conclude, which can be more useful to inhibit COVID-19 progression.
  • ||||||||||  bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal, Adverse events:  Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy. (Pubmed Central) -  Jan 8, 2021   
    Given widespread use of new antiretroviral drugs worldwide and anticipated use of new drugs, prospective follow-up of pregnant women and birth surveillance studies such as Tsepamo are critically needed.Neural tube defects have been reported among infants born from women taking a wide range of antiretrovirals in 4 pharmacovigilance databases. Safety reports were inconsistent between databases and very hard to interpret.
  • ||||||||||  Prezista (darunavir) / J&J, Copegus (ribavirin) / Bausch Health, Arbidol (umifenovir) / Pharmstandard
    Journal:  Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. (Pubmed Central) -  Dec 22, 2020   
    So far, chloroquine, lopinavir, hydroxychloroquine, azithromycin, favipiravir, ribavirin, darunavir, remdesivir, and umifenovir have been tested in COVID-19 clinical trials...Conversely, drugs with poor lung distributions, including lopinavir/ritonavir, umifenovir and remdesivir, were insufficient to inhibit viral replication...We concluded here that the antiviral drugs should be distributed straight to the lung tissue for reducing viral loads in respiratory tract of COVID-19 patients. Additionally, to better evaluate antiviral effects of drugs that target the intestine, the stool samples should also be collected for viral RNA test in the future.
  • ||||||||||  Journal:  Antiretroviral therapy and liver disorders in the OPERA cohort. (Pubmed Central) -  Dec 22, 2020   
    There were no DILI diagnoses and discontinuation of treatment following liver disorders was rare across all groups. Overall, the incidence of liver disorders after starting a new HIV treatment regimen did not differ between four common antiretroviral drugs.
  • ||||||||||  Relenza (zanamivir) / GSK, Vaxart
    Clinical, Review, Journal:  Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. (Pubmed Central) -  Dec 20, 2020   
    Antiviral drugs, such as remdesivir, ritonavir, oseltamivir, darunavir, lopinavir, zanamivir, peramivir, and oseltamivir, have also been tested as treatments for COVID-19...Mesenchymal stem cells and natural killer cells could also be used against SARS-CoV-2. All the above-mentioned strategies, as well as the role of nanomedicine for the diagnosis and treatment of SARS-CoV-2 infection, have been discussed in this review.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  Drug repurposing approach to fight COVID-19. (Pubmed Central) -  Dec 16, 2020   
    Using the basic knowledge of viral pathogenesis and pharmacodynamics of drugs as well as using computational tools, many drugs are currently in pipeline to be repurposed. In the current scenario, repositioning of the drugs could be considered the new avenue for the treatment of COVID-19.
  • ||||||||||  Clinical, Journal:  Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease. (Pubmed Central) -  Dec 15, 2020   
    Targeting of SARS-CoV-2 M by some of the HIV PIs might be of limited clinical potential, given the high concentration of the drugs required to achieve significant inhibition. Therefore, given their weak inhibition of the viral protease, any potential beneficial effect of the PIs in COVID-19 context might perhaps be attributed to acting on other molecular target(s), rather than SARS-CoV-2 M.